UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 269

Sortiert nach

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

Clinical pharmacokinetics, 2016-06, Vol.55 (6), p.657-672

2016

Volltextzugriff (PDF)

Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes

Diabetes, obesity & metabolism, 2018-09, Vol.20 (9), p.2238-2245

2018

Volltextzugriff (PDF)

Associations between postprandial insulin and blood glucose responses, appetite sensations and energy intake in normal weight and overweight individuals: a meta-analysis of test meal studies

British journal of nutrition, 2007-07, Vol.98 (1), p.17-25

2007

Volltextzugriff (PDF)

Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis

Diabetes therapy, 2018-08, Vol.9 (4), p.1533-1547

2018

Volltextzugriff (PDF)

The use of glycaemic index tables to predict glycaemic index of composite breakfast meals

British journal of nutrition, 2004-06, Vol.91 (6), p.979-989

2004

Volltextzugriff (PDF)

The influence of patient characteristics on the alarm rate in intensive care units: a retrospective cohort study

Scientific reports, 2022-12, Vol.12 (1), p.21801-21801, Article 21801

2022

Volltextzugriff (PDF)

Alarm Management in Intensive Care: Qualitative Triangulation Study

JMIR human factors, 2024-06, Vol.11, p.e55571

2024

Volltextzugriff (PDF)

Increased postprandial glycaemia, insulinemia, and lipidemia after 10 weeks' sucrose-rich diet compared to an artificially sweetened diet: a randomised controlled trial

Food & nutrition research, 2011-01, Vol.55 (1), p.5961-13

2011

Volltextzugriff (PDF)

ARTEMIS: An alarm threshold and policy mining system for the intensive care unit

International journal of medical informatics (Shannon, Ireland), 2024-04, Vol.184, p.105349-105349, Article 105349

2024

Volltextzugriff (PDF)

Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity

Diabetes, obesity & metabolism, 2017-09, Vol.19 (9), p.1242-1251

2017

Volltextzugriff (PDF)

A Standardized Clinical Data Harmonization Pipeline for Scalable AI Application Deployment (FHIR-DHP): Validation and Usability Study

JMIR medical informatics, 2023-03, Vol.11, p.e43847

2023

Volltextzugriff (PDF)

Effects of Different Dietary Fat Types on Postprandial Appetite and Energy Expenditure

Obesity (Silver Spring, Md.), 2003-12, Vol.11 (12), p.1449-1455

2003

Volltextzugriff (PDF)

Determinants of appetite ratings: the role of age, gender, BMI, physical activity, smoking habits, and diet/weight concern

Food & nutrition research, 2011-01, Vol.55 (1), p.7028

2011

Volltextzugriff (PDF)

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

Clinical pharmacokinetics, 2016-06, Vol.55 (6), p.657-672

2016

Volltextzugriff (PDF)

Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity

Diabetes, obesity & metabolism, 2018-03, Vol.20 (3), p.610-619

2018

Volltextzugriff (PDF)

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging

Alimentary pharmacology & therapeutics, 2021-11, Vol.54 (9), p.1150-1161

2021

Volltextzugriff (PDF)

Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel

Journal of clinical pharmacology, 2015-05, Vol.55 (5), p.497-504

2015

Volltextzugriff (PDF)

Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment

Clinical pharmacokinetics, 2017-11, Vol.56 (11), p.1381-1390

2017

Volltextzugriff (PDF)

Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial

Diabetologia, 2017-08, Vol.60 (8), p.1390-1399

2017

Volltextzugriff (PDF)

Patiëntenflow coördineren

TVZ - Verpleegkunde in praktijk en wetenschap, 2023-06, Vol.133 (3), p.33-35

2023

Volltextzugriff (PDF)

Patiëntenflow coördineren

TVZ - Verpleegkunde in praktijk en wetenschap, 2023-01, Vol.133 (3), p.33-35

2023

Volltextzugriff (PDF)

Editorial: evolution of GLP‐1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity – authors’ reply

Alimentary pharmacology & therapeutics, 2021-12, Vol.54 (11-12), p.1498-1498

2021

Volltextzugriff (PDF)

Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects

American journal of physiology: endocrinology and metabolism, 2007-04, Vol.292 (4), p.E1062-E1068

2007

Volltextzugriff (PDF)

Influence of hepatic impairment on pharmacokinetics of the human GLP‐1 analogue, liraglutide

British journal of clinical pharmacology, 2010-12, Vol.70 (6), p.807-814

2010

Volltextzugriff (PDF)

Effect of 3 modified fats and a conventional fat on appetite, energy intake, energy expenditure, and substrate oxidation in healthy men

The American journal of clinical nutrition, 2002, Vol.75 (1), p.47-56

2002

Volltextzugriff (PDF)

1 – 25 von 269

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(227)
Mit Volltextzugriff
(228)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(136)
Life Sciences & Biomedicine
(128)
Humans
(94)
Female
(43)
Adult
(41)
Biological And Medical Sciences
(40)
Male
(39)
Animals
(27)
Fundamental And Applied Biological Sciences. Psychology
(27)
Middle Aged
(27)
Endocrinology & Metabolism
(25)
Obesity
(21)
Aged
(19)
Nutrition & Dietetics
(19)
Insulin
(17)
Glucose
(16)
Medical Sciences
(16)
Medicine
(16)
Pharmacology & Pharmacy
(15)
Energy Intake
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes

Associations between postprandial insulin and blood glucose responses, appetite sensations and energy intake in normal weight and overweight individuals: a meta-analysis of test meal studies

Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis

The use of glycaemic index tables to predict glycaemic index of composite breakfast meals

The influence of patient characteristics on the alarm rate in intensive care units: a retrospective cohort study

Alarm Management in Intensive Care: Qualitative Triangulation Study

Increased postprandial glycaemia, insulinemia, and lipidemia after 10 weeks' sucrose-rich diet compared to an artificially sweetened diet: a randomised controlled trial

ARTEMIS: An alarm threshold and policy mining system for the intensive care unit

Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity

A Standardized Clinical Data Harmonization Pipeline for Scalable AI Application Deployment (FHIR-DHP): Validation and Usability Study

Effects of Different Dietary Fat Types on Postprandial Appetite and Energy Expenditure

Determinants of appetite ratings: the role of age, gender, BMI, physical activity, smoking habits, and diet/weight concern

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging

Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel

Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment

Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial

Patiëntenflow coördineren

Patiëntenflow coördineren

Editorial: evolution of GLP‐1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity – authors’ reply

Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects

Influence of hepatic impairment on pharmacokinetics of the human GLP‐1 analogue, liraglutide

Effect of 3 modified fats and a conventional fat on appetite, energy intake, energy expenditure, and substrate oxidation in healthy men

Suchergebnisse filtern